Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JACOB AELION

NPI
1679551501
CMS profile
167121
Location
JACKSON, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$32,280.45

201 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JACOB AELION

NPI 1679551501 · CMS profile ID 167121

JACKSON, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679551501?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JACOB AELION, NPI 1679551501, CMS profile ID 167121. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679551501?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JACOB AELION, NPI 1679551501, CMS profile ID 167121. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679551501?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JACOB AELION, NPI 1679551501, CMS profile ID 167121, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1679551501?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

201 matching records · $32,280.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 201 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 201.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.1407/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832536619 CMS
Lilly USA, LLC $2,450.0007/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937113161 CMS
AbbVie Inc. $20.4407/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810491 CMS
UCB, Inc. $14.9307/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807364463 CMS
Lilly USA, LLC $21.1106/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937113699 CMS
PFIZER INC. $10.9006/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832537855 CMS
AbbVie Inc. $12.3506/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810483 CMS
AbbVie Inc. $4.7806/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810487 CMS
Amgen Inc. $13.4906/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825370923 CMS
AbbVie Inc. $13.8906/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810479 CMS
Lilly USA, LLC $1,400.0006/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937113695 CMS
PFIZER INC. $6.9906/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832506733 CMS
Janssen Biotech, Inc. $15.7206/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788552249 CMS
GlaxoSmithKline, LLC. $17.5506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803044467 CMS
Amgen Inc. $12.1506/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825370983 CMS
Amgen Inc. $11.8406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825370919 CMS
Lilly USA, LLC $22.1606/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937107601 CMS
UCB, Inc. $17.4306/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807366741 CMS
UCB, Inc. $13.4606/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807370803 CMS
AbbVie Inc. $5.2006/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810471 CMS
AbbVie Inc. $13.5706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810475 CMS
Janssen Biotech, Inc. $10.0006/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788552279 CMS
Amgen Inc. $8.4006/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825370947 CMS
AbbVie Inc. $12.4605/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810467 CMS
AbbVie Inc. $14.0605/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810459 CMS
AbbVie Inc. $5.3905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810463 CMS
UCB, Inc. $15.1905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807349581 CMS
UCB, Inc. $13.0105/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807468097 CMS
Janssen Biotech, Inc. $13.0505/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788552257 CMS
Lilly USA, LLC $1,400.0005/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937113691 CMS
GlaxoSmithKline, LLC. $15.0105/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802209505 CMS
Amgen Inc. $15.4705/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825370943 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $24.9905/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814944333 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $15.2005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814943524 CMS
Janssen Biotech, Inc. $10.4205/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788552269 CMS
PFIZER INC. $15.9605/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832514711 CMS
Horizon Therapeutics plc $11.8705/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797057443 CMS
AbbVie Inc. $12.7605/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810451 CMS
AbbVie Inc. $3.8205/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810455 CMS
Janssen Biotech, Inc. $15.3504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788552255 CMS
Amgen Inc. $13.0004/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825370915 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $21.0304/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814943529 CMS
Lilly USA, LLC $20.9204/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937109369 CMS
AbbVie Inc. $15.6804/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810447 CMS
Amgen Inc. $9.6904/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825370979 CMS
AbbVie Inc. $15.8404/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810439 CMS
AbbVie Inc. $4.9504/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810443 CMS
Lilly USA, LLC $1,400.0004/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937113159 CMS
PFIZER INC. $17.1104/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832516795 CMS
AbbVie Inc. $16.7404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793810431 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $176,446.57 386
PY2020 $59,308.00 247
PY2021 $32,280.45 201
PY2022 $60,766.06 224
PY2023 $52,561.74 200
PY2024 $26,622.88 157
PY2025 $51,422.83 211

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,130,148.50 88
PY2024 Recipient $114.46 1
PY2024 Principal investigator $3,459,073.47 115
PY2023 Recipient $128.76 1
PY2023 Principal investigator $3,745,017.98 229
PY2022 Recipient $10.00 1
PY2022 Principal investigator $1,683,085.03 162
PY2021 Recipient $2,196.00 2
PY2021 Principal investigator $987,952.78 98
PY2020 Recipient $779.27 3
PY2020 Principal investigator $1,083,825.27 125
PY2019 Recipient $29,535.48 4
PY2019 Principal investigator $624,089.11 71

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $14,305.00 12/22/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175346528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,503.88 12/16/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTIT
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223289708
Principal investigator 1 ABBVIE INC. $2,121.50 12/04/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202528190
Principal investigator 1 ABBVIE INC. $4,385.88 12/04/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202528192
Principal investigator 1 ABBVIE INC. $1,156.08 12/04/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202528194
Principal investigator 1 Janssen Research & Development, LLC $7,085.00 11/28/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175346545
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,461.75 11/18/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTIT
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288379
Principal investigator 1 ABBVIE INC. $2,303.16 11/04/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202521203
Principal investigator 1 ABBVIE INC. $1,456.85 11/04/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202521205
Principal investigator 1 ABBVIE INC. $2,852.04 11/04/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202521207
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $858.87 11/04/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTIT
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223287939
Principal investigator 1 Janssen Research & Development, LLC $3,690.00 10/30/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175346564
Principal investigator 1 UCB SA $1,799.70 10/17/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658018
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,943.91 10/14/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTIT
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286767
Principal investigator 1 ABBVIE INC. $13,024.00 10/09/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202516217
Principal investigator 1 ABBVIE INC. $8,815.32 10/09/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516219
Principal investigator 1 ABBVIE INC. $3,921.85 10/09/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202516221
Principal investigator 1 ABBVIE INC. $1,759.32 10/09/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202516223
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $19,117.80 10/09/2025 Non-covered Recipient Entity
West Tennessee Research Institute
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus No dispute reported 06/30/2026 1235991698
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,906.47 10/02/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTIT
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223286247
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,747.81 09/18/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285690
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,296.62 09/18/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223285692
Principal investigator 1 ABBVIE INC. $2,181.10 09/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202508014
Principal investigator 1 ABBVIE INC. $2,124.96 09/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202508016
Principal investigator 1 Janssen Research & Development, LLC $4,492.00 08/28/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175346535
Principal investigator 1 Amgen Inc. $291.65 08/26/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE, LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246652123
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,790.91 08/19/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223284361
Principal investigator 1 ABBVIE INC. $1,834.56 08/05/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501284
Principal investigator 1 ABBVIE INC. $365.25 08/05/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202501286
Principal investigator 1 Janssen Research & Development, LLC $8,815.00 07/28/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175346554
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,349.24 07/22/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282938
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,250.00 07/17/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
An Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab Infusion in Adults With Giant Cell Arteritis (GCA) or Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190301347
Principal investigator 1 ABBVIE INC. $3,592.40 07/02/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202495431
Principal investigator 1 ABBVIE INC. $4,822.80 07/02/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202495433
Principal investigator 1 ABBVIE INC. $8,637.12 07/02/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202496123
Principal investigator 1 CSL Behring $87.64 06/16/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252665905
Principal investigator 1 CSL Behring $342.00 06/16/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252665907
Principal investigator 1 CSL Behring $359.00 06/16/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252665909
Principal investigator 1 CSL Behring $910.00 06/16/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252665911
Principal investigator 1 CSL Behring $1,238.00 06/16/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252665913
Principal investigator 1 CSL Behring $121.00 06/16/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252665915
Principal investigator 1 Eli Lilly and Company $1,232.00 06/10/2025 Non-covered Recipient Entity
WEST TENNESSE RESEARCH INSTITUTE
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187891562
Principal investigator 1 ABBVIE INC. $1,834.56 06/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202488353
Principal investigator 1 ABBVIE INC. $2,271.25 06/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202488355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,296.62 06/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223280584
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,832.00 05/22/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) No dispute reported 06/30/2026 1190301481
Principal investigator 1 Amgen Inc. $9,027.61 05/20/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246652140
Principal investigator 1 PFIZER INC. $6,348.50 05/20/2025 Non-covered Recipient Entity
West Tennessee Research Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND 3ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID19 WHO ARE SEVERELY IMMUNOCOMPROMISED No dispute reported 06/30/2026 1228707820
Principal investigator 1 PFIZER INC. $6,348.50 05/20/2025 Non-covered Recipient Entity
West Tennessee Research Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND 3ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID19 WHO ARE SEVERELY IMMUNOCOMPROMISED No dispute reported 06/30/2026 1228841661
Principal investigator 1 ABBVIE INC. $1,834.56 05/06/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202481729
Principal investigator 1 ABBVIE INC. $7,028.28 05/06/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481775
Principal investigator 1 ABBVIE INC. $1,104.70 05/06/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202481777
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,060.00 05/01/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223278782
Principal investigator 1 Eli Lilly and Company $72,492.00 04/15/2025 Non-covered Recipient Entity
WEST TENNESSE RESEARCH INSTITUTE
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187893330
Principal investigator 1 ABBVIE INC. $1,695.96 04/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202473092
Principal investigator 1 ABBVIE INC. $5,165.95 04/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202473096
Principal investigator 1 ABBVIE INC. $4,385.88 04/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202473112
Principal investigator 1 Amgen Inc. $6,000.00 04/03/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246652145
Principal investigator 1 Eli Lilly and Company $1,582.62 03/25/2025 Non-covered Recipient Entity
WEST TENNESSE RESEARCH INSTITUTE
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187893800
Principal investigator 1 UCB SA $13,941.00 03/21/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246658370
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,518.55 03/14/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235991694
Principal investigator 1 Amgen Inc. $36,914.72 03/11/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgrens Syndrome No dispute reported 06/30/2026 1246652135
Principal investigator 1 Eli Lilly and Company $414.00 03/10/2025 Non-covered Recipient Entity
WEST TENNESSE RESEARCH INSTITUTE
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187893332
Principal investigator 1 ABBVIE INC. $4,471.68 03/06/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202458553
Principal investigator 1 ABBVIE INC. $6,681.12 03/06/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202458557
Principal investigator 1 ABBVIE INC. $1,782.05 03/06/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202458680
Principal investigator 1 Amgen Inc. $143,521.45 02/25/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE, LLC
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246652127
Principal investigator 1 UCB SA $66,038.00 02/20/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246659104
Principal investigator 1 ABBVIE INC. $761.30 02/05/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202444573
Principal investigator 1 ABBVIE INC. $9,196.80 02/05/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202444609
Principal investigator 1 ABBVIE INC. $1,834.56 02/05/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202444613
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,719.14 01/28/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190301475
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,320.28 01/28/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension) No dispute reported 06/30/2026 1190301479
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,982.86 01/21/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235991692
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,436.31 01/21/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs No dispute reported 06/30/2026 1235991696
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 01/21/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223274267
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,000.00 01/16/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190301345
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,755.28 01/15/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy No dispute reported 06/30/2026 1190301349
Principal investigator 1 UCB SA $1.07 01/15/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657098
Principal investigator 1 Novartis Pharmaceuticals Corporation $320,338.32 01/14/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment No dispute reported 06/30/2026 1190300671
Principal investigator 1 CSL Behring $12,353.00 01/08/2025 Non-covered Recipient Entity
West Tennessee Research Institute
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) - The RECLAIIM Study No dispute reported 06/30/2026 1252665895
Principal investigator 1 Amgen Inc. $7,765.18 01/06/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE, LLC
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome No dispute reported 06/30/2026 1246652120
Principal investigator 1 ABBVIE INC. $3,936.30 01/02/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202434299
Principal investigator 1 ABBVIE INC. $4,385.88 01/02/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202434303
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,878.03 01/02/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease No dispute reported 06/30/2026 1190301473
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,652.90 01/02/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190301477
Principal investigator 1 Novartis Pharmaceuticals Corporation $538.37 01/01/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190301471
Principal investigator 1 Novartis Pharmaceuticals Corporation $69,351.92 01/01/2025 Non-covered Recipient Entity
WEST TENNESSEE RESEARCH INSTITUTE
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190301483